<DOC>
	<DOCNO>NCT02840695</DOCNO>
	<brief_summary>Ankylosing spondylitis ( AS ) rheumatoid disease affect segment axial skeleton , lead complete fusion spinal segment - bamboo-spine . During last decade biological disease modify anti-rheumatic drug ( bDMARD ) successfully introduce reduce disease activity . It unclear whether bDMARD treatment effect spinal fracture risk relate AS . This national registry study investigate effect bDMARD treatment spinal fracture risk national cohort patient AS .</brief_summary>
	<brief_title>Effect Biological Disease Modifying Anti Rheumatic Drug ( bDMARD ) Treatment Spinal Fracture Incidence Patients With Ankylosing Spondylitis ( AS )</brief_title>
	<detailed_description />
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Spinal Fractures</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>age 3060 year register diagnosis ankylose spondylitis age &lt; 30 &gt; 60 year</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>